Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Physicists and philosophers have long struggled to understand the nature of time: Here's why - 2Pick Your #1 Kind Of Bread
- 3How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- 4Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 5Picking the Right Air Purifier for Your Home
- Farmers worry about rising cost of fertiliser
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Looter indicted after pretending to be emergency worker at Dimona rocket crash site
- The most effective method to Pick The Right Speakers
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
